The Biotechnology Initiative (TBI) C-Level Forum – 2008 Series
"Building a Biotechnology Company – How to Leverage Partnership and Collaborations?"
In increasingly turbulent times, biotechnology executives continue to face tough questions from their boards and investors regarding the creation of shareholder value. One key avenue for building a biotech company – and driving its valuation – is the development of partnerships and collaborative agreements. TBI is pleased to host an exciting forum to discuss potential solutions regarding such partnership opportunities with your fellow C-suite executives. At this workshop, internationally renowned biotechnology executives with successful track records in surviving difficult market environments will share their experiences and lessons learned.
Date:
April 22, 2008 (Tuesday)
Time:
8:00 am - 8:30 am Registration
8:30 am - 3:45 pm Presentations
3:45 pm - 5:00 pm Cocktail Reception
9:00 am - 4:00 pm Exhibition
Location:
The Estates of Sunnybrook
Vaughan Estate
2075 Bayview Ave., Toronto, ON
www.estatesofsunnybrook.com/main/location.shtml
Registration Fee:
$200 (TBI members) $250 (non-members)
To Register Online Click Here
Intended Audience:
This meeting is specifically designed for senior management (CEOs, CSOs, CFOs or other senior executives) in the pharmaceutical, biotech or allied industries who wish to:
• explore various partnership and collaborative opportunities to maximize business opportunities
• learn critical business strategies related to the biotech or pharmaceutical industry
• strengthen knowledge and expertise in biopharmaceutical development
Learning Objectives:
Attendees will explore the core aspects of the biopharmaceutical sector, including the creation of partnerships as a key business strategy. Other critical business issues, e.g. pertaining to intellectual property, funding, outsourcing, and technical challenges (in chemistry, manufacturing and clinical research) will be discussed.
Program Agenda:
Morning Session (Facilitator: Dr. Bev Incledon, Director, Lilly Analytical Research Laboratory, Eli Lilly)
8:30 - 11:40 am Introductions and Opening Remarks
Grant Tipler, President, The Biotechnology Initiative
Keynote Address
Greg Hines, President and CEO, ArcticDx Inc.
The Myrex Story:
How a virtual pharmaceutical company can achieve Quantum Leap Results!
Jennifer Dewling, CEO, Myrex Pharmaceuticals
Building a pipeline through partnership and collaborations
Dr Aiping Young, CEO and President, Lorus Therapeutics
How to leverage China/India to create value for shareholders?
Denis Ho, Managing Director, Business Development Bank of Canada
11:40 - 12:30 pm LUNCH AND EXHIBITS
Lunch Presentation:
New Directions of the Regulatory Paradigm: Challenges in Regulatory Submissions: how to achieve, successfully, authorizations of biological/biotechnology based agents
Dr. Agnes Klein, Director, Centre for Evaluation of Radioharmaceuticals and Biotherapeutics, Biologics and Genetic Therapies Directorate, Health Canada
Afternoon Session (Facilitator: Lorne Meikle, CEO, Afference Therapeutics)
12:30 - 3:45 pm Legal perspectives for building partnership among biotech companies
Colin Ground, Partner, Cassels Brock & Blackwell LLP
Improve your chance of success in biotechnology industry
Dr. YC Lee, Senior Director, PharmEng Innovations
Financing product development in biopharma: Pairing equity capital with strategic partner capital - the issues and the opportunities and some best practice considerations
Peter van der Velden, President and CEO, Lumira Capital
Effective clinical research program for global submissions
Dr. Terry Sills, Vice President, Ontario Cancer Biomarker Network
3:45 - 5:00 pm Cocktail Reception & Close
Proud Sponsors of This Event:
Further information regarding April 22nd C-Level Forum: Please contact Chris Adams (chris@adamsrevers.com) or YC Lee (yc.l@pharmeng.com), or for Further information about TBI:click on www.ontbi.org
